APGE•benzinga•
Apogee Therapeutics Released Interim Data From Its Phase 1b Trial Of APG808, A Novel Half-life Extended IL-4Rα Antibody, In Patients With Mild-to-moderate Asthma
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga